Loading...
•
Mar 31, 2022
Amedisys Q1 2022 Earnings Report
Amedisys reported financial results for Q1 2022, showing increased net service revenue but decreased net income compared to Q1 2021.
Key Takeaways
Amedisys reported a slight increase in net service revenue to $545.3 million, but net income decreased to $31.7 million. The company reaffirmed its 2022 guidance, anticipating adjusted net service revenue between $2.330 billion and $2.365 billion.
Net service revenue increased to $545.3 million from $537.1 million in the same period last year.
Net income attributable to Amedisys, Inc. decreased to $31.7 million from $49.9 million in the same period last year.
Adjusted net income attributable to Amedisys, Inc. was $40.1 million, compared to $51.1 million in the prior year.
The company reaffirmed its full-year 2022 guidance for adjusted net service revenue, adjusted EBITDA, and adjusted diluted earnings per share.
Forward Guidance
Amedisys reaffirmed its previously issued guidance for 2022, excluding the effects of any future acquisitions.
Positive Outlook
- Adjusted net service revenue is anticipated to be in the range of $2.330 billion to $2.365 billion.
- Adjusted EBITDA is anticipated to be in the range of $275 million to $285 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $5.23 to $5.45.
- Guidance is based on an estimated 33.2 million shares outstanding.
- The company's differentiated strategy presents significant opportunities.
Challenges Ahead
- COVID-19 has continued to impact the operating metrics used to forecast growth and cost assumptions.
- Future regulations or government interventions could impact the ability to achieve guidance.
- Spike in clinicians and business development staff on quarantine could impact the ability to achieve guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...